Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Medicine (Baltimore) ; 101(9): e28790, 2022 Mar 04.
Article En | MEDLINE | ID: mdl-35244037

ABSTRACT: There is no information concerning the prevalence of thalassemia among pregnant women in Hubei Province currently. This study is aimed to explore the prevalence of α- and ß-thalassemia genotypes among pregnant women in Hubei Province, and to explore the clinically applicable screening approach, as well as to investigate the pregnancy outcomes of α- and ß-thalassemia carriers.Pregnant participants were recruited from 4 hospitals for the screening of α- and ß-thalassemia mutations in Hubei Province. Polymerase Chain Reaction and flow cytometry methods were used to examine α- and ß-thalassemia mutations. The hematological parameters and pregnancy outcomes of α- and ß-thalassemia carriers were obtained from the hospital information system. The chi-square tests were used to evaluate the difference in hematological parameters between pregnant thalassemia carriers and the control group.Among 11,875 participants, 414 (3.49%) were confirmed with α-thalassemia carriers, 228 (1.92%) were confirmed with ß-thalassemia carriers, and 3 (0.03%) were confirmed with both α- and ß-thalassemia carriers. The frequency of -α3.7 accounted for 2.05% and it was the most frequent genotype of α-thalassemia; the proportion of IVS-II-654 was 0.85% and it was the most frequent genotype of ß-thalassemia in Hubei Province. Furthermore, the proportion of patients with low mean corpuscular volume (MCV) or mean cell hemoglobin (MCH) values was accounted for 36.64% and 93.97% among α-thalassemia and ß-thalassemia carriers, respectively. And participants with normal MCV and MCH values were accounted for 95.07% among non-thalassemia participants. High prevalence of pregnancy-induced diabetes (16.97%), preterm birth (9.96%), pregnancy-induced hypertension (8.12%), and low birth weight (5.90%) were observed among pregnant thalassemia carriers.MCV and MCH values were suggested to apply on the preliminary screening of pregnant ß-thalassemia; however, it's unpractical on that of α-thalassemia. Furthermore, thalassemia carriers might have a high risk of negative pregnancy outcomes. These findings could be useful for the preliminary screening of thalassemia and perinatal care for the pregnant thalassemia carriers.


Pregnancy Complications, Hematologic/epidemiology , alpha-Thalassemia/epidemiology , beta-Thalassemia/epidemiology , China/epidemiology , Diabetes, Gestational/epidemiology , Female , Genotype , Hemoglobins , Humans , Hypertension, Pregnancy-Induced/epidemiology , Infant, Low Birth Weight , Infant, Newborn , Male , Polymerase Chain Reaction , Pregnancy , Pregnant Women , Premature Birth/epidemiology , Prevalence , alpha-Thalassemia/diagnosis , alpha-Thalassemia/genetics , beta-Thalassemia/diagnosis , beta-Thalassemia/genetics
2.
Med Oncol ; 38(11): 132, 2021 Sep 28.
Article En | MEDLINE | ID: mdl-34581882

WAC is closely related to the occurrence and development of tumors. However, its role in human glioblastoma (GBM) and its potential regulatory mechanisms have not been investigated. This study demonstrated that WAC is downregulated in GBM, and its low expression predicts a poor prognosis. We investigated the effect of WAC on the proliferation of glioma cells through a CCK-8 assay, EdU incorporation, and cell formation. The effects of WAC on apoptosis and autophagy in glioma were determined by flow cytometry, TUNEL detection, immunofluorescence, q-PCR, WB, and scanning electron microscopy. We found that overexpression of WAC inhibited the proliferation of glioma cells, promoted apoptosis, and induced autophagy. Therefore, WAC is likely to play a role as a new regulatory molecule in glioma.


Adaptor Proteins, Signal Transducing/physiology , Apoptosis , Autophagy/physiology , Brain Neoplasms/pathology , Glioblastoma/pathology , Tumor Suppressor Proteins/physiology , Brain Neoplasms/mortality , Brain Neoplasms/prevention & control , Cell Line, Tumor , Cell Proliferation , Glioblastoma/mortality , Glioblastoma/prevention & control , Humans , Signal Transduction
3.
J Mater Chem B ; 6(28): 4592-4601, 2018 Jul 28.
Article En | MEDLINE | ID: mdl-32254403

Photodynamic therapy (PDT) has been widely applied in cancer treatment due to minimal invasion, negligible side effects and specific tumor ablation. However, the treatment efficiency has been hindered by hypoxia in solid tumors, hydrophobic photosensitizers and their real time tracking. In this paper, we constructed an intelligent and biocompatible bovine serum albumin (BSA)-Ce6-Si QDs-MnO2 (BCSM NPs) nanocomplex as a pH/H2O2 responsive photosensitizer nanocarrier to modulate tumor hypoxia for fluorescence imaging-guided efficient PDT. This versatile nanosystem not only enhanced the loading capacity of the photosensitizer and the formation of cytotoxic singlet oxygen (1O2) owing to the intelligent production of oxygen catalyzed by MnO2 from the endogenous H2O2, but also performed as a dual functional fluorescence and Magnetic Resonance imaging (MRI) probe. In vivo experiments in nude mice further confirmed that BCSM NPs significantly inhibited the growth of HeLa bearing-tumors compared to free Ce6. The results highlight the great potentail of multifunctional BCSM NPs for in vivo imaging as well as enhancing the photodynamic therapy efficiency.

...